{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:44:30Z","timestamp":1785735870881,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00347-021-01376-7","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T14:02:58Z","timestamp":1618581778000},"page":"967-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chorioretinopathia centralis serosa","Central serous chorioretinopathy"],"prefix":"10.1007","volume":"118","author":[{"given":"Laurenz","family":"Pauleikhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00fcrgen","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF02720786","volume":"12","author":"A Von Graefe","year":"1866","unstructured":"Von Graefe\u00a0A (1866) \u00dcber zentrale rezidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol 12:221","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"Suppl","key":"1376_CR2","first-page":"1","volume":"63","author":"JD Gass","year":"1967","unstructured":"Gass\u00a0JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1\u2013139","journal-title":"Am J Ophthalmol"},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","volume":"86","author":"M Wang","year":"2008","unstructured":"Wang\u00a0M, Munch\u00a0IC, Hasler\u00a0PW et\u00a0al (2008) Central serous chorioretinopathy. Acta Ophthalmol 86:126\u2013145. https:\/\/doi.org\/10.1111\/j.1600-0420.2007.00889.x","journal-title":"Acta Ophthalmol"},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann\u00a0AS, Pulido\u00a0JS, Diehl\u00a0NN et\u00a0al (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology 115:169\u2013173. https:\/\/doi.org\/10.1016\/j.ophtha.2007.02.032","journal-title":"Ophthalmology"},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0161-6420(96)30386-2","volume":"103","author":"RF Spaide","year":"1996","unstructured":"Spaide\u00a0RF, Campeas\u00a0L, Haas\u00a0A et\u00a0al (1996) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070\u20132079 (discussion 2079\u20132080)","journal-title":"Ophthalmology"},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0161-6420(96)30730-6","volume":"103","author":"DA Quillen","year":"1996","unstructured":"Quillen\u00a0DA, Gass\u00a0JDM, Brod\u00a0RD et\u00a0al (1996) Central serous chorioretinopathy in women. Ophthalmology 103:72\u201379. https:\/\/doi.org\/10.1016\/S0161-6420(96)30730-6","journal-title":"Ophthalmology"},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","volume":"33","author":"E Bousquet","year":"2013","unstructured":"Bousquet\u00a0E, Beydoun\u00a0T, Zhao\u00a0M et\u00a0al (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:2096\u20132102. https:\/\/doi.org\/10.1097\/IAE.0b013e318297a07a","journal-title":"Retina"},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich\u00a0A, Matet\u00a0A, Dirani\u00a0A et\u00a0al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82\u2013118. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/s0161-6420(02)01117-x","volume":"109","author":"CA Carvalho-Recchia","year":"2002","unstructured":"Carvalho-Recchia\u00a0CA, Yannuzzi\u00a0LA, Negr\u00e3o\u00a0S et al (2002) Corticosteroids and central serous chorioretinopathy. Ophthalmology 109:1834\u20131837. https:\/\/doi.org\/10.1016\/s0161-6420(02)01117-x","journal-title":"Ophthalmology"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0161-6420(02)01975-9","volume":"110","author":"R Haimovici","year":"2003","unstructured":"Haimovici\u00a0R, Rumelt\u00a0S, Melby\u00a0J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698\u2013703. https:\/\/doi.org\/10.1016\/S0161-6420(02)01975-9","journal-title":"Ophthalmology"},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s0021-5155(97)00027-0","volume":"41","author":"M Wakakura","year":"1997","unstructured":"Wakakura\u00a0M, Song\u00a0E, Ishikawa\u00a0S (1997) Corticosteroid-induced central serous chorioretinopathy. Jpn J Ophthalmol 41:180\u2013185. https:\/\/doi.org\/10.1016\/s0021-5155(97)00027-0","journal-title":"Jpn J Ophthalmol"},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao\u00a0M, C\u00e9l\u00e9rier\u00a0I, Bousquet\u00a0E et\u00a0al (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J\u00a0Clin Invest 122:2672\u20132679. https:\/\/doi.org\/10.1172\/JCI61427","journal-title":"J Clin Invest"},{"key":"1376_CR13","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1096\/fj.09-154344","volume":"24","author":"M Zhao","year":"2010","unstructured":"Zhao\u00a0M, Valamanesh\u00a0F, Celerier\u00a0I et al (2010) The neuroretina is a\u00a0novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells. FASEB\u00a0J 24:3405\u20133415. https:\/\/doi.org\/10.1096\/fj.09-154344","journal-title":"FASEB J"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.mehy.2004.02.020","volume":"63","author":"C Giusti","year":"2004","unstructured":"Giusti\u00a0C (2004) Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses 63:524\u2013527. https:\/\/doi.org\/10.1016\/j.mehy.2004.02.020","journal-title":"Med Hypotheses"},{"key":"1376_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.oret.2019.08.002","volume":"3","author":"J Siedlecki","year":"2019","unstructured":"Siedlecki\u00a0J, Schworm\u00a0B, Priglinger\u00a0SG (2019) The Pachychoroid disease spectrum-and the need for a\u00a0uniform classification system. Ophthalmol Retina 3:1013\u20131015. https:\/\/doi.org\/10.1016\/j.oret.2019.08.002","journal-title":"Ophthalmol Retina"},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/IAE.0000000000000837","volume":"36","author":"B Liu","year":"2016","unstructured":"Liu\u00a0B, Deng\u00a0T, Zhang\u00a0J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9\u201319. https:\/\/doi.org\/10.1097\/IAE.0000000000000837","journal-title":"Retina"},{"key":"1376_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1176\/appi.psy.48.6.489","volume":"48","author":"R Conrad","year":"2007","unstructured":"Conrad\u00a0R, Weber\u00a0NF, Lehnert\u00a0M et\u00a0al (2007) Alexithymia and emotional distress in patients with central serous chorioretinopathy. Psychosomatics 48:489\u2013495. https:\/\/doi.org\/10.1176\/appi.psy.48.6.489","journal-title":"Psychosomatics"},{"key":"1376_CR18","doi-asserted-by":"publisher","first-page":"631687","DOI":"10.1155\/2014\/631687","volume":"2014","author":"R Conrad","year":"2014","unstructured":"Conrad\u00a0R, Geiser\u00a0F, Kleiman\u00a0A et al (2014) Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal 2014:631687. https:\/\/doi.org\/10.1155\/2014\/631687","journal-title":"ScientificWorldJournal"},{"key":"1376_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-198700720-00009","volume":"7","author":"LA Yannuzzi","year":"1987","unstructured":"Yannuzzi\u00a0LA (1987) Type\u2011A behavior and central serous chorioretinopathy. Retina 7:111\u2013131. https:\/\/doi.org\/10.1097\/00006982-198700720-00009","journal-title":"Retina"},{"key":"1376_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamaophthalmol.2017.0245","volume":"135","author":"EHC van Dijk","year":"2017","unstructured":"van Dijk\u00a0EHC, Schellevis\u00a0RL, van Bergen\u00a0MGJM et\u00a0al (2017) Association of a\u00a0Haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. JAMA Ophthalmol 135:446\u2013451. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0245","journal-title":"JAMA Ophthalmol"},{"key":"1376_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ophtha.2014.09.026","volume":"122","author":"EK de Jong","year":"2015","unstructured":"de Jong\u00a0EK, Breukink\u00a0MB, Schellevis\u00a0RL et al (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562\u2013570. https:\/\/doi.org\/10.1016\/j.ophtha.2014.09.026","journal-title":"Ophthalmology"},{"key":"1376_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ophtha.2013.11.020","volume":"121","author":"A Miki","year":"2014","unstructured":"Miki\u00a0A, Kondo\u00a0N, Yanagisawa\u00a0S et\u00a0al (2014) Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology 121:1067\u20131072. https:\/\/doi.org\/10.1016\/j.ophtha.2013.11.020","journal-title":"Ophthalmology"},{"key":"1376_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ophtha.2003.09.024","volume":"111","author":"R Haimovici","year":"2004","unstructured":"Haimovici\u00a0R, Koh\u00a0S, Gagnon\u00a0DR et al (2004) Risk factors for central serous chorioretinopathy: a\u00a0case-control study. Ophthalmology 111:244\u2013249. https:\/\/doi.org\/10.1016\/j.ophtha.2003.09.024","journal-title":"Ophthalmology"},{"key":"1376_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaophthalmol.2016.0090","volume":"134","author":"ML Weber","year":"2016","unstructured":"Weber\u00a0ML, Liang\u00a0MC, Flaherty\u00a0KT, Heier\u00a0JS (2016) Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol 134:855\u2013862. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.0090","journal-title":"JAMA Ophthalmol"},{"key":"1376_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000333824","volume":"227","author":"K Aliferis","year":"2012","unstructured":"Aliferis\u00a0K, Petropoulos\u00a0IK, Farpour\u00a0B et\u00a0al (2012) Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 227:85\u201389. https:\/\/doi.org\/10.1159\/000333824","journal-title":"Ophthalmologica"},{"key":"1376_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0002-9394(03)00076-x","volume":"136","author":"JC Michael","year":"2003","unstructured":"Michael\u00a0JC, Pak\u00a0J, Pulido\u00a0J, de Venecia\u00a0G (2003) Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol 136:182\u2013185. https:\/\/doi.org\/10.1016\/s0002-9394(03)00076-x","journal-title":"Am J Ophthalmol"},{"key":"1376_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/ICB.0b013e31818ad3ce","volume":"3","author":"KK Pierce","year":"2009","unstructured":"Pierce\u00a0KK, Lane\u00a0RG (2009) Central serous chorioretinopathy associated with the use of ephedra. Retin Cases Brief Rep 3:376\u2013378. https:\/\/doi.org\/10.1097\/ICB.0b013e31818ad3ce","journal-title":"Retin Cases Brief Rep"},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/bjo.68.11.815","volume":"68","author":"CM Gilbert","year":"1984","unstructured":"Gilbert\u00a0CM, Owens\u00a0SL, Smith\u00a0PD, Fine\u00a0SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815\u2013820","journal-title":"Br J Ophthalmol"},{"key":"1376_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/s0161-6420(89)32810-7","volume":"96","author":"R Levine","year":"1989","unstructured":"Levine\u00a0R, Brucker\u00a0AJ, Robinson\u00a0F (1989) Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 96:854\u2013859. https:\/\/doi.org\/10.1016\/s0161-6420(89)32810-7","journal-title":"Ophthalmology"},{"key":"1376_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","volume":"22","author":"RH Loo","year":"2002","unstructured":"Loo\u00a0RH, Scott\u00a0IU, Flynn\u00a0HW et al (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19\u201324. https:\/\/doi.org\/10.1097\/00006982-200202000-00004","journal-title":"Retina"},{"key":"1376_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/IAE.0b013e3181fbce8e","volume":"31","author":"I Maruko","year":"2011","unstructured":"Maruko\u00a0I, Iida\u00a0T, Ojima\u00a0A, Sekiryu\u00a0T (2011) Subretinal dot-like precipitates and yellow material in central serous Chorioretinopathy. Retina 31:759\u2013765. https:\/\/doi.org\/10.1097\/IAE.0b013e3181fbce8e","journal-title":"Retina"},{"key":"1376_CR32","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1167\/iovs.12-10991","volume":"54","author":"L Yang","year":"2013","unstructured":"Yang\u00a0L, Jonas\u00a0JB, Wei\u00a0W (2013) Optical coherence tomography\u2013assisted enhanced depth imaging of central serous Chorioretinopathy. Invest Ophthalmol Vis Sci 54:4659. https:\/\/doi.org\/10.1167\/iovs.12-10991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1376_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/IAE.0000000000000742","volume":"36","author":"KK Dansingani","year":"2016","unstructured":"Dansingani\u00a0KK, Balaratnasingam\u00a0C, Naysan\u00a0J, Freund\u00a0KB (2016) En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 36:499\u2013516. https:\/\/doi.org\/10.1097\/IAE.0000000000000742","journal-title":"Retina"},{"key":"1376_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IAE.0000000000000287","volume":"35","author":"M Lehmann","year":"2015","unstructured":"Lehmann\u00a0M, Bousquet\u00a0E, Beydoun\u00a0T, Behar-Cohen\u00a0F (2015) Pachychoroid: an inherited condition? Retina 35:10\u201316. https:\/\/doi.org\/10.1097\/IAE.0000000000000287","journal-title":"Retina"},{"key":"1376_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/eye.2013.78","volume":"27","author":"JH Kim","year":"2013","unstructured":"Kim\u00a0JH, Kang\u00a0SW, Kim\u00a0JR, Kim\u00a0SJ (2013) Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy. Eye 27:809\u2013815. https:\/\/doi.org\/10.1038\/eye.2013.78","journal-title":"Eye"},{"key":"1376_CR36","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1167\/iovs.11-8383","volume":"53","author":"S Usui","year":"2012","unstructured":"Usui\u00a0S, Ikuno\u00a0Y, Akiba\u00a0M et\u00a0al (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Investig Ophthalmol Vis Sci 53:2300\u20132307. https:\/\/doi.org\/10.1167\/iovs.11-8383","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1376_CR37","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1167\/iovs.09-4383","volume":"51","author":"Y Ikuno","year":"2010","unstructured":"Ikuno\u00a0Y, Kawaguchi\u00a0K, Nouchi\u00a0T, Yasuno\u00a0Y (2010) Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 51:2173\u20132176. https:\/\/doi.org\/10.1167\/iovs.09-4383","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1376_CR38","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/IAE.0000000000002294","volume":"38","author":"Y Sakurada","year":"2018","unstructured":"Sakurada\u00a0Y, Leong\u00a0BCS, Parikh\u00a0R et\u00a0al (2018) Association between choroidal caverns and choroidal vascular hyperpermeability in eyes with pachychoroid diseases. Retina 38:1977\u20131983. https:\/\/doi.org\/10.1097\/IAE.0000000000002294","journal-title":"Retina"},{"key":"1376_CR39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ajo.2015.08.018","volume":"160","author":"RF Spaide","year":"2015","unstructured":"Spaide\u00a0RF, Ryan\u00a0EH (2015) Loculation of fluid in the posterior choroid in eyes with central serous Chorioretinopathy. Am J Ophthalmol 160:1211\u20131216. https:\/\/doi.org\/10.1016\/j.ajo.2015.08.018","journal-title":"Am J Ophthalmol"},{"key":"1376_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072260","author":"M Battista","year":"2020","unstructured":"Battista\u00a0M, Borrelli\u00a0E, Veronese\u00a0C et\u00a0al (2020) Choroidal rift: a new OCT finding in eyes with central serous Chorioretinopathy. JCM. https:\/\/doi.org\/10.3390\/jcm9072260","journal-title":"JCM"},{"key":"1376_CR41","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1755-3768.2008.01468.x","volume":"87","author":"C Ahlers","year":"2009","unstructured":"Ahlers\u00a0C, Geitzenauer\u00a0W, Stock\u00a0G et\u00a0al (2009) Alterations of intraretinal layers in acute central serous chorioretinopathy. Acta Ophthalmol 87:511\u2013516. https:\/\/doi.org\/10.1111\/j.1755-3768.2008.01468.x","journal-title":"Acta Ophthalmol"},{"key":"1376_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00417-019-04524-7","volume":"258","author":"J Yang","year":"2020","unstructured":"Yang\u00a0J, Wang\u00a0E, Yuan\u00a0M, Chen\u00a0Y (2020) Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 258:241\u2013247. https:\/\/doi.org\/10.1007\/s00417-019-04524-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1376_CR43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00347-010-2154-3","volume":"107","author":"H Baraki","year":"2010","unstructured":"Baraki\u00a0H, Feltgen\u00a0N, Roider\u00a0J et\u00a0al (2010) Chorioretinopathia centralis serosa (CCS). Ophthalmologe 107:479\u2013493. https:\/\/doi.org\/10.1007\/s00347-010-2154-3","journal-title":"Ophthalmologe"},{"key":"1376_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001580","author":"E Bousquet","year":"2017","unstructured":"Bousquet\u00a0E, Bonnin\u00a0S, Mrejen\u00a0S et\u00a0al (2017) Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous Chorioretinopathy. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000001580","journal-title":"Retina"},{"key":"1376_CR45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00347-012-2588-x","volume":"109","author":"V Valet","year":"2012","unstructured":"Valet\u00a0V, Lohmann\u00a0CP, Maier\u00a0M (2012) Spectral domain OCT in central serous chorioretinopathy: description of retinal changes. Ophthalmologe 109:879\u2013887. https:\/\/doi.org\/10.1007\/s00347-012-2588-x","journal-title":"Ophthalmologe"},{"key":"1376_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajo.2007.08.024","volume":"145","author":"H Matsumoto","year":"2008","unstructured":"Matsumoto\u00a0H, Kishi\u00a0S, Otani\u00a0T, Sato\u00a0T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162\u2013168. https:\/\/doi.org\/10.1016\/j.ajo.2007.08.024","journal-title":"Am J Ophthalmol"},{"key":"1376_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1600-0420.2005.00442.x","volume":"83","author":"C Framme","year":"2005","unstructured":"Framme\u00a0C, Walter\u00a0A, Gabler\u00a0B et al (2005) Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand 83:161\u2013167. https:\/\/doi.org\/10.1111\/j.1600-0420.2005.00442.x","journal-title":"Acta Ophthalmol Scand"},{"key":"1376_CR48","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ophtha.2005.01.003","volume":"112","author":"RF Spaide","year":"2005","unstructured":"Spaide\u00a0RF, Klancnik\u00a0JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825\u2013833. https:\/\/doi.org\/10.1016\/j.ophtha.2005.01.003","journal-title":"Ophthalmology"},{"key":"1376_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/bjo.2008.141564","volume":"93","author":"A Ayata","year":"2009","unstructured":"Ayata\u00a0A, Tatlipinar\u00a0S, Kar\u00a0T et al (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79\u201382. https:\/\/doi.org\/10.1136\/bjo.2008.141564","journal-title":"Br J Ophthalmol"},{"key":"1376_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s003470050367","volume":"96","author":"A von R\u00fcckmann","year":"1999","unstructured":"von R\u00fcckmann\u00a0A, Schmidt\u00a0KG, Fitzke\u00a0FW et\u00a0al (1999) Serous central chorioretinopathy. Acute autofluorescence of the pigment epithelium of the eye. Ophthalmologe 96:6\u201310. https:\/\/doi.org\/10.1007\/s003470050367","journal-title":"Ophthalmologe"},{"key":"1376_CR51","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/s0002-9394(02)01428-9","volume":"133","author":"A von R\u00fcckmann","year":"2002","unstructured":"von R\u00fcckmann\u00a0A, Fitzke\u00a0FW, Fan\u00a0J et\u00a0al (2002) Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 133:780\u2013786. https:\/\/doi.org\/10.1016\/s0002-9394(02)01428-9","journal-title":"Am J Ophthalmol"},{"key":"1376_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00417-009-1212-5","volume":"248","author":"D Bujarborua","year":"2010","unstructured":"Bujarborua\u00a0D, Nagpal\u00a0PN, Deka\u00a0M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339\u2013351. https:\/\/doi.org\/10.1007\/s00417-009-1212-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1376_CR53","doi-asserted-by":"publisher","first-page":"CR51","DOI":"10.12659\/msm.882455","volume":"18","author":"U Gajdzik-Gajdecka","year":"2012","unstructured":"Gajdzik-Gajdecka\u00a0U, Dorecka\u00a0M, Nita\u00a0E et al (2012) Indocyanine green angiography in chronic central serous chorioretinopathy. Med Sci Monit 18:CR51\u2013CR57. https:\/\/doi.org\/10.12659\/msm.882455","journal-title":"Med Sci Monit"},{"key":"1376_CR54","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archopht.1994.01090200063023","volume":"112","author":"DR Guyer","year":"1994","unstructured":"Guyer\u00a0DR (1994) Digital Indocyanine green Videoangiography of central serous Chorioretinopathy. Arch Ophthalmol 112:1057. https:\/\/doi.org\/10.1001\/archopht.1994.01090200063023","journal-title":"Arch Ophthalmol"},{"key":"1376_CR55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jamaophthalmol.2015.1320","volume":"133","author":"MA Bonini Filho","year":"2015","unstructured":"Bonini Filho\u00a0MA, de Carlo\u00a0TE, Ferrara\u00a0D et\u00a0al (2015) Association of choroidal neovascularization and central serous Chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.1320","journal-title":"JAMA Ophthalmol"},{"key":"1376_CR56","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ophtha.2015.01.029","volume":"122","author":"TE de Carlo","year":"2015","unstructured":"de Carlo\u00a0TE, Bonini Filho\u00a0MA, Chin\u00a0AT et al (2015) Spectral-domain optical coherence tomography angiography of choroidal neovascularization. Ophthalmology 122:1228\u20131238. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.029","journal-title":"Ophthalmology"},{"key":"1376_CR57","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen\u00a0TJ, van Dijk\u00a0EHC, Yzer\u00a0S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"key":"1376_CR58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","volume":"149","author":"LA Yannuzzi","year":"2010","unstructured":"Yannuzzi\u00a0LA (2010) Central serous chorioretinopathy: a\u00a0personal perspective. Am J Ophthalmol 149:361\u2013363. https:\/\/doi.org\/10.1016\/j.ajo.2009.11.017","journal-title":"Am J Ophthalmol"},{"key":"1376_CR59","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/ph13080170","volume":"13","author":"R Venkatesh","year":"2020","unstructured":"Venkatesh\u00a0R, Pereira\u00a0A, Jayadev\u00a0C et\u00a0al (2020) Oral Eplerenone versus observation in the management of acute central serous chorioretinopathy: a prospective, randomized comparative study. Pharmaceuticals 13:170. https:\/\/doi.org\/10.3390\/ph13080170","journal-title":"Pharmaceuticals"},{"key":"1376_CR60","unstructured":"Lange et\u00a0al Stellungnahme des Berufsverbandes der Augen\u00e4rzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS) Stand 2020. https:\/\/www.dog.org\/wp-content\/uploads\/2013\/03\/Stellungsnahme-Chorioretinopathia-centralis-serosa-CCS-2020_12-1.pdf. Zugegriffen: 1. Febr. 2021"},{"key":"1376_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2415-4-15","volume":"4","author":"L Verma","year":"2004","unstructured":"Verma\u00a0L, Sinha\u00a0R, Venkatesh\u00a0P, Tewari\u00a0H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484. BMC Ophthalmol 4:15. https:\/\/doi.org\/10.1186\/1471-2415-4-15","journal-title":"BMC Ophthalmol"},{"key":"1376_CR62","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s12325-017-0559-y","volume":"34","author":"P Scholz","year":"2017","unstructured":"Scholz\u00a0P, Altay\u00a0L, Fauser\u00a0S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528\u20131555. https:\/\/doi.org\/10.1007\/s12325-017-0559-y","journal-title":"Adv Ther"},{"key":"1376_CR63","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s00417-006-0368-5","volume":"244","author":"H Elsner","year":"2006","unstructured":"Elsner\u00a0H, P\u00f6rksen\u00a0E, Klatt\u00a0C et\u00a0al (2006) Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 244:1638\u20131645. https:\/\/doi.org\/10.1007\/s00417-006-0368-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1376_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/bjo.2009.178327","volume":"95","author":"C Klatt","year":"2011","unstructured":"Klatt\u00a0C, Saeger\u00a0M, Oppermann\u00a0T et\u00a0al (2011) Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 95:83\u201388. https:\/\/doi.org\/10.1136\/bjo.2009.178327","journal-title":"Br J Ophthalmol"},{"key":"1376_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/bjo.84.1.40","volume":"84","author":"J Roider","year":"2000","unstructured":"Roider\u00a0J, Brinkmann\u00a0R, Wirbelauer\u00a0C et\u00a0al (2000) Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a\u00a0pilot study. Br J Ophthalmol 84:40\u201347. https:\/\/doi.org\/10.1136\/bjo.84.1.40","journal-title":"Br J Ophthalmol"},{"key":"1376_CR66","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/IAE.0000000000001386","volume":"37","author":"EH Wood","year":"2017","unstructured":"Wood\u00a0EH, Karth\u00a0PA, Sanislo\u00a0SR et\u00a0al (2017) Nondamaging retinal laser therapy for treatment of central serous Chorioretinopathy: what is the evidence? Retina 37:1021\u20131033. https:\/\/doi.org\/10.1097\/IAE.0000000000001386","journal-title":"Retina"},{"key":"1376_CR67","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","volume":"87","author":"W-M Chan","year":"2003","unstructured":"Chan\u00a0W\u2011M, Lam\u00a0DSC, Lai\u00a0TYY et al (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a\u00a0novel treatment at the primary disease level. Br J Ophthalmol 87:1453\u20131458","journal-title":"Br J Ophthalmol"},{"key":"1376_CR68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/jop.2019.0003","volume":"36","author":"JH Lee","year":"2020","unstructured":"Lee\u00a0JH, Lee\u00a0SC, Lee\u00a0CS (2020) Comparison of half-time and half-Irradiance photodynamic therapy in Nonresolving central serous Chorioretinopathy. J\u00a0Ocular Pharmacol Ther 36:109\u2013115. https:\/\/doi.org\/10.1089\/jop.2019.0003","journal-title":"J Ocular Pharmacol Ther"},{"key":"1376_CR69","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","volume":"115","author":"W-M Chan","year":"2008","unstructured":"Chan\u00a0W\u2011M, Lai\u00a0TYY, Lai\u00a0RYK et al (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a\u00a0randomized controlled trial. Ophthalmology 115:1756\u20131765. https:\/\/doi.org\/10.1016\/j.ophtha.2008.04.014","journal-title":"Ophthalmology"},{"key":"1376_CR70","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","volume":"37","author":"C-K Cheng","year":"2017","unstructured":"Cheng\u00a0C\u2011K, Chang\u00a0C\u2011K, Peng\u00a0C\u2011H (2017) Comparison of photodynamic therapy using half-dose of Verteporfin or half-Fluence of laser light for the treatment of chronic central serous Chorioretinopathy. Retina 37:325\u2013333. https:\/\/doi.org\/10.1097\/IAE.0000000000001138","journal-title":"Retina"},{"key":"1376_CR71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","volume":"149","author":"M Reibaldi","year":"2010","unstructured":"Reibaldi\u00a0M, Cardascia\u00a0N, Longo\u00a0A et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a\u00a0nonrandomized clinical trial. Am J Ophthalmol 149:307\u2013315.e2. https:\/\/doi.org\/10.1016\/j.ajo.2009.08.026","journal-title":"Am J Ophthalmol"},{"key":"1376_CR72","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ajo.2010.08.019","volume":"151","author":"F Senturk","year":"2011","unstructured":"Senturk\u00a0F, Karacorlu\u00a0M, Ozdemir\u00a0H et\u00a0al (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303\u2013309.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.08.019","journal-title":"Am J Ophthalmol"},{"key":"1376_CR73","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/FTD.0b013e31820beb02","volume":"31","author":"ZHY Wu","year":"2011","unstructured":"Wu\u00a0ZHY, Lai\u00a0RYK, Yip\u00a0YWY et al (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a\u00a0randomized placebo-controlled trial. Retina 31:1378\u20131386. https:\/\/doi.org\/10.1097\/FTD.0b013e31820beb02","journal-title":"Retina"},{"key":"1376_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000490773","volume":"241","author":"BK Son","year":"2019","unstructured":"Son\u00a0BK, Kim\u00a0K, Kim\u00a0ES, Yu\u00a0S\u2011Y (2019) Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica 241:105\u2013115. https:\/\/doi.org\/10.1159\/000490773","journal-title":"Ophthalmologica"},{"key":"1376_CR75","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk\u00a0EHC, Fauser\u00a0S, Breukink\u00a0MB et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous Chorioretinopathy. Ophthalmology 125:1547\u20131555. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021","journal-title":"Ophthalmology"},{"key":"1376_CR76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2020.04.007","volume":"216","author":"TJ van Rijssen","year":"2020","unstructured":"van Rijssen\u00a0TJ, van Dijk\u00a0EHC, Scholz\u00a0P et\u00a0al (2020) Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous Chorioretinopathy: the REPLACE trial. Am J Ophthalmol 216:80\u201389. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.007","journal-title":"Am J Ophthalmol"},{"key":"1376_CR77","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10384-019-00697-0","volume":"64","author":"Y-I Shin","year":"2020","unstructured":"Shin\u00a0Y\u2011I, Kim\u00a0K\u2011M, Lee\u00a0M\u2011W et al (2020) Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy. Jpn J Ophthalmol 64:28\u201336. https:\/\/doi.org\/10.1007\/s10384-019-00697-0","journal-title":"Jpn J Ophthalmol"},{"key":"1376_CR78","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/IAE.0000000000002507","volume":"40","author":"DY Kim","year":"2020","unstructured":"Kim\u00a0DY, Lee\u00a0JY, Lee\u00a0EK, Kim\u00a0JY (2020) Comparison of visual\/anatomical outcomes and recurrence rate between oral spironolactone and photodynamic therapy for nonresolving central serous Chorioretinopathy. Retina 40:1191\u20131199. https:\/\/doi.org\/10.1097\/IAE.0000000000002507","journal-title":"Retina"},{"key":"1376_CR79","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/IAE.0000000000001913","volume":"39","author":"JH Lee","year":"2019","unstructured":"Lee\u00a0JH, Lee\u00a0SC, Kim\u00a0H, Lee\u00a0CS (2019) Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous Chorioretinopathy. Retina 39:127\u2013133. https:\/\/doi.org\/10.1097\/IAE.0000000000001913","journal-title":"Retina"},{"key":"1376_CR80","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/02713680903428306","volume":"35","author":"O Artunay","year":"2010","unstructured":"Artunay\u00a0O, Yuzbasioglu\u00a0E, Rasier\u00a0R et\u00a0al (2010) Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 35:91\u201398. https:\/\/doi.org\/10.3109\/02713680903428306","journal-title":"Curr Eye Res"},{"key":"1376_CR81","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/112067211002000524","volume":"20","author":"L Konstantinidis","year":"2010","unstructured":"Konstantinidis\u00a0L, Mantel\u00a0I, Zografos\u00a0L, Ambresin\u00a0A (2010) Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous Chorioretinopathy. Eur J Ophthalmol 20:955\u2013958. https:\/\/doi.org\/10.1177\/112067211002000524","journal-title":"Eur J Ophthalmol"},{"key":"1376_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","volume":"58","author":"B Nicholson","year":"2013","unstructured":"Nicholson\u00a0B, Noble\u00a0J, Forooghian\u00a0F, Meyerle\u00a0C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103\u2013126. https:\/\/doi.org\/10.1016\/j.survophthal.2012.07.004","journal-title":"Surv Ophthalmol"},{"key":"1376_CR83","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00347-018-0785-y","volume":"116","author":"B Cakir","year":"2019","unstructured":"Cakir\u00a0B, Agostini\u00a0H, Lange\u00a0C (2019) Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists. Ophthalmologe 116:189\u2013200. https:\/\/doi.org\/10.1007\/s00347-018-0785-y","journal-title":"Ophthalmologe"},{"key":"1376_CR84","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery\u00a0A, Sivaprasad\u00a0S, O\u2019Connell\u00a0A et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4\u00a0months (VICI): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 395:294\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(19)32981-2","journal-title":"Lancet"},{"key":"1376_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13491","author":"R Schwartz","year":"2017","unstructured":"Schwartz\u00a0R, Habot-Wilner\u00a0Z, Martinez\u00a0MR et al (2017) Eplerenone for chronic central serous chorioretinopathy\u2011a randomized controlled prospective study. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.13491","journal-title":"Acta Ophthalmol"},{"key":"1376_CR86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2018.09.034","volume":"198","author":"E Bousquet","year":"2019","unstructured":"Bousquet\u00a0E, Dhundass\u00a0M, Lejoyeux\u00a0R et\u00a0al (2019) Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous Chorioretinopathy. Am J Ophthalmol 198:80\u201387. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.034","journal-title":"Am J Ophthalmol"},{"key":"1376_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120952648","author":"D Fraenkel","year":"2020","unstructured":"Fraenkel\u00a0D, Suffo\u00a0S, Langenbucher\u00a0A et\u00a0al (2020) Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/1120672120952648","journal-title":"Eur J Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01376-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-021-01376-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01376-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:42:00Z","timestamp":1630669320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-021-01376-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1007\/s00347-021-01376-7","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"15 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>L.\u00a0Pauleikhoff<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Dr. Werner Jackst\u00e4dt-Stiftung. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Freiburg. <b>H.\u00a0Agostini<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Leihger\u00e4t Fa.\u00a0Zeiss (institutionell).\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Zeiss Meditec (institutionell). \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Arzt, Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: DOG, BVA, Vorstand von Retinologischer Gesellschaft, retina.net, BDOC. <b>C.\u00a0Lange<\/b>: A.\u00a0Finanzielle Interessen: kein finanzieller Interessenkonflikt.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Klinik f\u00fcr Augenheilkunde, Universit\u00e4t Freiburg | Mitgliedschaft: DOG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}